Osimertinib/osimertinib latest price in 2024

Osimertinib is a targeted drug used to treat non-small cell lung cancer (NSCLC), also known as AZD9291. It belongs to the third generation of epidermal growth factor receptor (EGFR) inhibitors. Compared with traditional first- and second-generation drugs, Osimertinib has higher selectivity and stronger inhibitory effect.

Osimertinib/The original drug of Osimertinib has been launched in the domestic market and has been included in the national medical insurance system. Domestic patients can purchase this drug directly locally, and the price is roughly in the range of three to four thousand yuan. Regarding the specific selling price and medical insurance reimbursement details, it is recommended that patients or family members go to the pharmacy of the local hospital for detailed consultation. In comparison, there are some more affordable generic drugs available in foreign markets, especially those in Laos and Bangladesh. Most of them cost only a few hundred yuan, which is far lower than the domestic price level. It is worth mentioning that these generic drugs maintain a high degree of consistency with the original drugs in terms of pharmaceutical ingredients.

Osimertinib/The mechanism of action of Osimertinib is to block the transmission of cancer cell growth signals by inhibiting EGFR activity. Compared with other first- and second-generation drugs, Osimertinib is more selective for EGFR mutations, especially the common EGFR T790M resistance mutation. This mutation is one of the main mechanisms leading to drug resistance in NSCLC.

Clinical studies have shown that osimertinib/osimertinib has shown significant efficacy in the treatment of NSCLC patients. Especially for those advanced NSCLC patients with EGFR T790M mutations, osimertinib/osimertinibOften an effective treatment option. It can prolong patient survival and improve quality of life.

In addition to its highly selective inhibitory effect on EGFR T790M mutations, osimertinib/osimertinib also exhibits lower levels of toxic side effects, making it one of the safer treatment options for NSCLC patients. Common side effects may include dry skin, diarrhea, drowsiness, etc., but are generally well tolerated.

In general, the emergence of osimertinib/osimertinib has brought new treatment hope to patients with advanced NSCLC. However, the issue of resistance to this drug still requires close attention, and further research and clinical practice are needed to refine treatment options to improve patient prognosis and survival.